October 20, 2016
Theravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
October 18, 2016
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV(R) (telavancin), Including Ongoing TOUR(TM) Observational Patient Registry, at IDWeek 2016
October 6, 2016
Theravance Biopharma Announces New Employment Inducement Awards
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: